Anemia de Células Falciformes: Correlación Clínico-Patológica

Contenido principal del artículo

María Antonia Correa Saavedra

Resumen

La anemia de células falciformes es la alteración hematológica heredada más común a nivel mundial. Esta dada por la presencia de hemoglobinas anormales (HbS y sus diferentes genotipos) a raíz de una mutación en las cadenas de globina. La tríada clínica consiste en eventos vaso-oclusivos, anemia hemolítica crónica y asplenia funcional. Hoy en día se ha documentado toda clase de complicaciones asociadas a la enfermedad, entre las cuales se encuentran: accidentes cerebrovasculares, infarto agudo de miocardio, hipertensión pulmonar, tromboembolismos venosos, infecciones, necrosis de la papila renal, enfermedad renal crónica, ulceraciones en miembros inferiores, enfermedades del aparato hepatobiliar y necrosis ósea avascular. Es de vital importancia la realización de un correcto enfoque clínico y terapéutico de los pacientes con anemia de células falciformes de modo que sea posible la prevención y tratamiento oportuno de las complicaciones asociadas a esta condición.

Detalles del artículo

Sección
Artículos de Revisión de Tema
Biografía del autor/a

María Antonia Correa Saavedra, Universidad Pontificia Bolivariana

Estudiante de Medicina. Universidad Pontificia Bolivariana.

Citas

1. Alrayyes S, Baghdan D, Haddad RY, Compton AA, Mohama S, Goreishi R, et al. Sickle cell disease; An overview of the disease and its systemic effects. Dis Mon 2018; 64(6):283-289. DOI:10.1016/j.disamonth.2017.12.003.
2. Martins RA, Soares RS, Vito FB, Barbosa VF, Silva SS, Moraes-Souza H, et al. Cholelithiasis and its complications in sickle cell disease in a university hospital. Rev Bras Hematol Hemoter 2017; 39(1):28-31. DOI: 10.1016/j.bjhh.2016.09.009.
3. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med 2017; 376(5):429-439. DOI: 10.1056/NEJMoa1611770.
4. Atwood CM, Gnagi SH, Teufel RJ 2nd, Nguyen SA, White DR. Blood transfusion in children with sickle cell disease undergoing tonsillectomy. Int J Pediatr Otorhinolaryngol 2017; 103:117-120. DOI: 10.1016/j.ijporl.2017.10.013.
5. Willen SM, DeBaun MR. The Epidemiology and Management of Lung Diseases in Sickle Cell Disease: Lessons Learned from Acute and Chronic Lung Disease in Cystic Fibrosis. Pediatr Clin North Am 2018; 65(3):481-493. DOI: 10.1016/j.pcl.2018.01.007.
6. Brewin J, Howard J. Sickle cell disease: an update on management. Paediatr Child Health 2017; 27(11):506-510. DOI: doi.org/10.1016/j.paed.2017.07.005.
7. Fasano RM, Meier ER, Hulbert ML. Cerebral vasculopathy in children with sickle cell anemia. Blood Cells Mol Dis 2015; 54(1):17-25. DOI:10.1016/j.bcmd.2014.08.007.
8. Fong C, Menzel S, Lizarralde MA, Barreto G. Genetic variants associated with fetal hemoglobin levels show the diverse ethnic origin in Colombian patients with sickle cell anemia. Biomedica 2015; 35(3):437-43. DOI: 10.7705/biomedica.v35i3.2573.
9. Rosero MJ, Bermúdez AJ. Analysis of hemoglobinopathies in afro-colombian regions using dried blood samples of umbilical cord. Acta Med Colomb 2012; 37(3):118-124.
10. Du M, Van Ness S, Gordeuk V, Nouraie SM, Nekhai S, Gladwin M, et al. Biomarker signatures of sickle cell disease severity. Blood Cells Mol Dis 2018; 72:1-9. DOI:10.1016/j.bcmd.2018.05.001.
11. Sant'Ana PG, Araujo AM, Pimenta CT, Bezerra ML, Junior SP, Neto VM, et al. Clinical and laboratory profile of patients with sickle cell anemia. Rev Bras Hematol Hemoter 2017; 39(1):40-45. DOI:10.1016/j.bjhh.2016.09.007.
12. Henderickx MMEL, Brits T, De Baets K, Seghers M, Maes P, Trouet D, et al. Renal papillary necrosis in patients with sickle cell disease: How to recognize this 'forgotten' diagnosis. J Pediatr Urol 2017; 13(3):250-256. DOI: 10.1016/j.jpurol.2017.01.020.
13. Jitraruch S, Fitzpatrick E, Deheragoda M, Deganello A, Mieli-Vergani G, Height S. Autoimmune Liver Disease in Children with Sickle Cell Disease. J Pediatr 2017; 189:79-85.e2. DOI: 10.1016/j.jpeds.2017.06.035.
14. Wang MX, Pepin EW, Verma N, Mohammed TL. Manifestations of sickle cell disease on thoracic imaging. Clin Imaging 2018; 48:1-6. DOI:10.1016/j.clinimag.2017.09.001.
15. Esrick EB, Bauer DE. Genetic therapies for sickle cell disease. SEMIN HEMATOL Journal 2018: 1-11. DOI: 10.1053/j.seminhematol.2018.04.014.
16. Jayavaradhan R, Malik P. Genetic Therapies for Sickle Cell Disease. Pediatr Clin North Am 2018; 65(3):465-480. DOI: 10.1016/j.pcl.2018.01.008.
17. Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: An update. Cytotherapy 2018; pii: S1465-3249:(18)30486-30489. DOI:10.1016/j.jcyt.2018.04.003.
18. Meier ER. Treatment Options for Sickle Cell Disease. Pediatr Clin North Am 2018; 65(3):427-443. DOI: 10.1016/j.pcl.2018.01.005.
19. Sethy S, Panda T, Jena RK. Beneficial Effect of Low Fixed Dose of Hidroxyurea in Vaso-oclussive Crisis and Transfusion Requirements in Adult HbSS Patients: A Prospective Study in a Tertiary Care Center. Indian J Hematol Blood Transfus 2018; 34(2): 294-298. DOI: 10.1007/s12288-017-0869-x.
20. Alayash AI. Oxidative pathways in the sickle cell and beyond. Blood Cells Mol Dis 2018; 70:78-86. DOI: 10.1016/j.bcmd.2017.05.009.
21. Kozanoglu I, Ozdogu H. Use of red blood cell exchange for treating acute complications of sickle cell disease. Transfus Apher Sci 2018; 57(1):23-26. DOI: 10.1016/j.transci.2018.02.011.
22. Möckesch B, Charlot K, Jumet S, Romana M, Divialle-Doumdo L, Hardy-Dessources MD, et al. Micro- and macrovascular function in children with sickle cell anaemia and sickle cell haemoglobin C disease. Blood Cells Mol Dis 2017; 64:23-29. DOI: 10.1016/j.bcmd.2017.02.001.
23. Renoux C, Joly P, Faes C, Mury P, Eglenen B, Turkay M, et al. Association between Oxidative Stress, Genetic Factors, and Clinical Severity in Children with Sickle Cell Anemia. J Pediatr 2018; 195:228-235. DOI: 10.1016/j.jpeds.2017.12.021.
24. Thein MS, Igbineweka NE, Thein SL. Sickle cell disease in the older adult. Pathology 2017; 49(1):1-9. DOI: 10.1016/j.pathol.2016.10.002.
25. Boettger PC, Knupp CL, Liles DK, Walker K. Vitamin D Deficiency in Adult Sickle Cell Patients. J Natl Med Assoc 2017; 109(1):36-43. DOI: 10.1016/j.jnma.2016.10.003.
26. Ayala AJ, González HJ, David GJ. Sickle Cell Anemia: A review. Salud Uninorte 2016; 32(3):513-527.
27. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet 2017; 390(10091):311-323. DOI:10.1016/S0140-6736(17)30193-9.
28. Jones S, Duncan ER, Thomas N, Walters J, Dick MC, Height SE, Stephens AD, et al. Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haematol 2005; 131(4):530-533.
29. Yallop D, Duncan ER, Norris E, Fuller GW, Thomas N, Walters J, et al. The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. Br J Haematol 2007; 136(6):844-848.
30. Nolan VG, Zhang Y, Lash T, Sebastiani P, Steinberg MH. Association between wind speed and the occurrence of sickle cell acute painful episodes: results of a case-crossover study. Br J Haematol 2008; 143(3):433-438. DOI:10.1111/j.1365-2141.2008.07354.x.
31. Barbosa SM, Farhat SC, Martins LC, Pereira LA, Saldiva PH, Zanobetti A,et al. Air pollution and children's health: sickle cell disease. Cad Saude Publica 2015; 31(2):265-275.
32. Brandow AM, DeBaun MR. Key Components of Pain Management for Children and Adults with Sickle Cell Disease. Hematol Oncol Clin North Am 2018; 32(3):535-550. DOI: 10.1016/j.hoc.2018.01.014.
33. Darbari DS, Vaughan KJ, Roskom K, Seamon C, Diaw L, Quinn M, et al. Central sensitization associated with low fetal hemoglobin levels in adults with sickle cell anemia. Scand J Pain 2017; 17:279-286. DOI:10.1016/j.sjpain.2017.08.001.
34. Thiam L, Dramé A, Coly IZ, Diouf FN, Seck N, Boiro D, et al. [Epidemiological, clinical and hematological profiles of homozygous sickle cell disease during the intercritical period among children in Ziguinchor, Senegal]. Pan Afr Med J 2017; 28:208. DOI:10.11604/pamj.2017.28.208.14006.
35. Bilong Y, Dubert M, Koki G, Noubiap JJ, Pangetna HN, Menet A, et al. Sickle cell retinopathy and other chronic complications of sickle cell anemia: A clinical study of 84 Sub-Saharan African cases (Cameroon). J Fr Ophtalmol 2018; 41(1):50-56. DOI: 10.1016/j.jfo.2017.07.005.
36. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med 2014; 371(8):699-710. DOI: 10.1056/NEJMoa1401731.
37. Morrone KA, Pecker LH, Rand J, Davila J, Oyeku S, Little JA, Xiaonan X,et al. Association of silent infarcts in sickle cell anemia with decreased annexin A5 resistance. Blood Cells Mol Dis 2018; 69:53-56. DOI:10.1016/j.bcmd.2017.09.001.
38. Steven A, Raghavan P, Rath TJ, Gandhi D. Neurologic and Head and Neck Manifestations of Sickle Cell Disease. Hematol Oncol Clin North Am 2016; 30(4):779-98. DOI: 10.1016/j.hoc.2016.03.004.
39. Olowoyo P, Owolabi MO, Fawale B, Ogunniyi A. Short term stroke outcome is worse among indiv1iduals with sickle cell trait. eNeurologicalSci 2016;3:64-68.
40. De Luna G, Ranque B, Courbebaisse M, Ribeil JA, Khimoud D, Dupeux S, et al. High bone mineral density in sickle cell disease: Prevalence and characteristics. Bone 2018; 110:199-203. DOI:10.1016/j.bone.2018.02.003.
41. Linton E, Langer AL, Glassberg J. Hospital Admissions, Mortality and Comorbidities Among New York State Sickle Cell Patients, 2005-2013. J Natl Med Assoc 2018; 110(2):149-156. DOI: 10.1016/j.jnma.2017.10.006.
42. Ma JD, El-Jawahri AR, LeBlanc TW, Roeland EJ. Pain Syndromes and Management in Adult Hematopoietic Stem Cell Transplantation. Hematol Oncol Clin North Am 2018; 32(3):551-567. DOI: 10.1016/j.hoc.2018.01.012.
43. Nelson DA, Deuster PA, Carter R 3rd, Hill OT, Wolcott VL, Kurina LM. Sickle Cell Trait, Rhabdomyolysis, and Mortality among U.S. Army Soldiers. N Engl J Med 2016; 375(5):435-42. DOI: 10.1056/NEJMoa1516257.
44. Noubouossie D, Key NS. Sickle cell disease and venous thromboembolism in pregnancy and the puerperium. Thromb Res 2015; 135 Suppl 1:S46-8. DOI:10.1016/S0049-3848(15)50442-8.
45. Woods GM, Sharma R, Creary S, O'Brien S, Stanek J, Hor K, et al. Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study. J Pediatr 2018; 197:186-190.e1. DOI:10.1016/j.jpeds.2018.01.073.
46. Maioli MC, Soares AR, Bedirian R, Alves UD, de Lima Marinho C, Lopes AJ. Relationship between pulmonary and cardiac abnormalities in sickle cell disease: implications for the management of patients. Rev Bras Hematol Hemoter 2016; 38(1):21-7. DOI: 10.1016/j.bjhh.2015.11.001.
47. Saied DA, El-Raziky MS, El-Ghamrawy MK, Mahmoud MA. The pattern of hepatobiliary complications among Egyptian sickle cell disease children. Gaz Egypt Paediatr Assoc 2017 (65): 54-59. DOI: 10.1016/j.epag.2017.04.002
48. Martins RA, Soares RS, Vito FB, Barbosa VF, Silva SS, Moraes-Souza H, et al. Cholelithiasis and its complications in sickle cell disease in a university hospital. Rev Bras Hematol Hemoter 2017; 39(1):28-31. DOI:10.1016/j.bjhh.2016.09.009.
49. Saraf SL, Sysol JR, Susma A, Setty S, Zhang X, Gudehithlu KP, et al. Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models. Transl Res 2018; 197:1-11. DOI: 10.1016/j.trsl.2018.01.007.
50. Yee ME, Lane PA, Archer DR, Joiner CH, Eckman JR, Guasch A. Losartan therapy decreases albuminuria with stable glomerular filtration and permselectivity in sickle cell anemia. Blood Cells Mol Dis 2018; 69:65-70. DOI:10.1016/j.bcmd.2017.09.006.